Vitamin D3 and Depression

Armin Moradi

2021-04-13

Overview

Introduction

  • ? Vitamin D3 supplementation to prevent depression

Rationale (why care?)

  • It's a vitamin, must be good!
  • Many people already take it
  • Depression has one of the largest economic burdens in the world

Primary Goals

  • Does vitamin D3 supplementation affect risk of depression?
  • Spoiler: no!

Methods

  • Double-blind
  • Randomized
  • Placebo controlled
  • 18,353 participants 50 and older
  • 2011 to 2017, median treatment duration of 5.3 years

Results

  • No dice!

Author's Conclusion

  • No good!

Diving head first!

Authors

Funding and Support

  • Pharmavite LLC (vitamin D3) and Pronova BioPharma/BASF (Omacor fish oil)
  • Grants from NIMH, NCI, NHLBI

Conflict of interest

  • None reported

Introduction

Background and rationale

  • Depression: leading cause of disease burden and disability
  • Often undertreated in older persons
  • Public health priority

Hypothesis and research question

  • Hypothesis: high doses D3 supplementation is effective in preventing incidence or recurrence of late-life depression
  • Objective: to evaluate the effectiveness of high dose D3 supplementation on depression prevention
  • Primary outcomes: total risk of depression or clinically relevant depressive symptoms (both recurrence and incidence) and long-term trajectory of mood based on 6 annual assessments

Methods

Design

  • VITAL > VITAL-DEP
  • Double-blind, Placebo-controlled
  • large sample size
  • 2x2 factorial design (?)

Recruitment

  • No information on method of recruitment was provided
  • No information on compensation

Screening

  • No pre-screening information was provided
  • inclusion criteria
    • appears to be no depression hx and depression hx but no tx for past 2 years
  • Exclusion criteria
    • hx of CA or CV
    • D3 or fish oil intake
    • some medical disorders: renal failure, hypercalcemia, hypo/hyper-parathyroidism,
    • cirrhosis, granulomatous disease
    • AND MORE!

Participants

  • 18353, 9181, 9172, 9181, 9172
  • 2000 IU/d D3, 840mg omega-3 fatty acids as placebo
  • even distribution

Administration

  • Administration regimen not discussed

Assessment and Follow up

  • 5 year annual follow up via mailed questionnaires
  • follow up until end-point, death, or end of trial

Primary Analysis

  • designed for power >=85%, actual powah >99%!
  • Cumulative incidence curves
  • Cox proportional hazards models
  • linear models
  • Wald test (?)

Secondary Analyses

  • some more analyses
  • also post-hoc

Results

Scores

  • 609 cases of depression in D3 group, 625 in placebo group
  • adjusted HR was 0.97 (95% CI, 0.87 to 1.09; Pā€‰=ā€‰0.62)
  • difference between PHQ-8 between two groups: 0.01 points; 95% CI, āˆ’0.04 to 0.05 points

Scores 2.0

follow up vs baseline mean change in PHQ-8 between groups P-value
1y -0.01 0.84
2y 0.03 0.35
3y 0.01 0.63
4y -0.01 0.73
5y 0.03 0.40
Overall 0.01 0.72

Statistical Significant

  • No significance

Clinical Significance

  • no bueno for 25-hydroxyvitamin D

Reliability

  • The good
    • Primary outcome based on objective measures (PHQ-8)
    • large sample size
    • 100% rate of completion
    • Double blind
    • Similar groups at the start of the study, treated equally except treatment
    • All patients analyzed
  • The bad
    • ?
  • The ugly
    • ?

Generally Reliable

Conclusion

Statistical Interpretation

  • There isn't much room for artistic interpretation
  • laaaarge P-value = no statistical significance

Limitations

  • annual PHQ-8s
  • self-reported mood and depression variables were of uncertain validity
  • good baseline D3 levels

Conclusion

  • No Bueno! :(

Conclusion 2.0

These findings do not support the use of vitamin D3 in adults to prevent depression.

Discussion

  • Results appropriately interpreted
  • Adequately explained limitations except
    • Medication administration process
  • Consistent conclusion
  • Generalizable? Not quite
    • Ethnicity, age
  • Literature correspondence? Yes
    • Vitamin D supplementation and depression prevention
      • doi: 10.1001/jama.2019.0556
      • doi: 10.1093/ajcn/nqz141
      • doi: 10.1016/j.jad.2016.03.022
      • doi: 10.1017/jns.2018.19

Clinical practice

  • No change at this point

Future

  • Children and young adults
  • Starting with mild D3 deficiency

QA?